Downloads: 116
Review Papers | Pharmacology Science | India | Volume 4 Issue 1, January 2015
Risk and Benefits of Canagliflozin, a New Sodium-Glucose Co-Transporter Type 2 Inhibitor, in the Treatment of type-2 Diabetes Mellitus
Md Shadab Alam [2] | Satish Chandra [3] | Janardan Sharma
Abstract: Anti-diabetic medications are used to control blood sugar levels if diet and exercise fail to do so. On March 29, 2013, canagliflozin became the first SGLT2 inhibitor to be approved in the United States for the treatment of type-2 diabetes. This drug blocks reabsorption of glucose in the proximal tubule, lowering the renal threshold for glucose and thereby increasing glucose excretion. Its novel mechanism of action is insulin-independent. In clinical trials, canagliflozin significantly decreased fasting glucose and HbA1c level when administered either as monotherapy or as combined therapy with other anti-diabetic drugs, with added benefit of weight loss and lowering of blood pressure. It possesses favourable pharmacokinetic and pharmacodynamic profiles. It is administered orally and may be a viable option for adults with Type-2 DM who cannot achieve glycemic control with multiple agents but refuse injectable medications. However, it is not devoid of unfavourable adverse effects like urinary tract infections, genital yeast infections, postural hypotension, hyperkalemia, dose-dependent increases in low-density lipoprotein cholesterol etc. Canagliflozine should not be used in chronic kidney disease due to decreased or lack of efficacy and nephrotoxicity.
Keywords: Type 2 diabetes, Canagliflozin, SGLT2 inhibitor, HbA1c, Weight loss, Hypoglycemia, urinary tract infections, Genital Infection, Chronic kidney disease
Edition: Volume 4 Issue 1, January 2015,
Pages: 1320 - 1323
Similar Articles with Keyword 'Type 2 diabetes'
Downloads: 3 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1
Case Studies, Pharmacology Science, India, Volume 10 Issue 8, August 2021
Pages: 1039 - 1040Sitagliptin induced Stevens Johnson Syndrome in an Elderly Diabetic Patient
Megha Garg [2] | Girish Joseph [2] | Neena Bhatti [2] | Riya Y Mittal
Downloads: 104
Research Paper, Pharmacology Science, Iraq, Volume 4 Issue 3, March 2015
Pages: 2155 - 2157Administration of Tadalafil to Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Prospective Randomized Clinical Trial
Haedar Abdulhafith Al-Biati | Qassim AL-Shamaa | Sajida Hussein Ismail [3] | Faris Abdul Kareem Kazaal | Salim Al-Rubaie